Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lytix Biopharma AS ( (DE:6BG) ) has issued an update.
Lytix Biopharma AS has announced the approval of 4,910,484 share options under its long-term incentive program to replace expired options and incentivize management. This move is intended to align management with shareholder interests and support the company’s strategic goals in advancing its clinical pipeline towards commercial success.
More about Lytix Biopharma AS
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company specializing in host-defense peptide-derived molecules. Their lead product, LTX-315, is an oncolytic molecule aimed at enhancing anti-cancer immunity, with a pipeline targeting various cancer indications in mono- and combination therapies.
YTD Price Performance: 35.71%
Average Trading Volume: 77,025
Current Market Cap: NOK544.7M
For detailed information about 6BG stock, go to TipRanks’ Stock Analysis page.